Ratings Friulchem S.p.A.

Equities

FCM

IT0005378457

Market Closed - Borsa Italiana Other stock markets 11:44:59 2024-05-08 am EDT			5-day change	1st Jan Change
0.93 ^EUR	0.00%		-1.59%	-7.00%

Mar. 22	Friulchem returns to profit in 2023; increases financial debt	AN
Mar. 22	Friulchem S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.51 for the 2023 fiscal year.
The company appears to be poorly valued given its net asset value.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
The group shows a rather high level of debt in proportion to its EBITDA.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
FRIULCHEM S.P.A.	-7.00%	6.01M	-
ELI LILLY AND COMPANY	+33.40%	700B	C+
JOHNSON & JOHNSON	-4.79%	358B	C+
MERCK & CO., INC.	+18.85%	330B	B-
ABBVIE INC.	+3.42%	287B	C+
ASTRAZENECA PLC	+15.70%	236B	B+
NOVARTIS AG	+6.68%	202B	B-
ROCHE HOLDING AG	-9.08%	197B	A+
AMGEN INC.	+5.71%	161B	C+
PFIZER, INC.	-2.06%	157B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes